DECISION : Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial

• Tyrosine Kinase inhibitors are indicated in patients with a significant DTC tumor burden, symptomatic, rapidly progressive and/or imminently threatening disease. (ATA thyroid cancer guidelines 2015)

• Lenvatinib, another TKI was also efficacious in DTC (SELECT study)

Infographic

Reference

Brose, Marcia S et al. “Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.” Lancet (London, England) vol. 384,9940 (2014): 319-28.